# Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags

> **Open Intelligence Dossier** · First detected: 2026-09-25 04:40 UTC · Category: Business

## Executive Summary
Kyverna is leveraging one-year miv-cel durability data to position its CAR T-cell therapy as a leading autoimmune treatment amid peer safety concerns.

## Intelligence Brief
Kyverna is reporting one-year data for its miv-cel therapy, which demonstrates durable, drug-free remission and a strong safety profile. This cell therapy is being targeted at patients with Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG). According to reports from TradingView and STAT, the data indicates a lasting autoimmune benefit for those treated. The company is utilizing these findings to support its goal of achieving a complete Biologics License Application (BLA) submission for the treatment of Stiff Person Syndrome within the current year. Coverage from Fierce Biotech emphasizes that Kyverna is attempting to 'reset the conversation' regarding autoimmune CAR-T therapies. This strategic pivot comes as other peers in the same therapeutic space have encountered safety snags, making Kyverna's reported safety record a focal point.


BioSpace highlights that the company is moving closer to becoming the first to receive FDA approval for a CAR T-cell therapy specifically indicated for an autoimmune condition. This momentum is further supported by H.C. Wainwright, which reiterated its stock rating for Kyverna following the release of the durability data. Understanding the significance of this trend requires noting the rare nature of the target conditions and the novelty of applying CAR T-cell technology to autoimmune diseases rather than oncology. Endpoints News reports that the long-term data is intended to bolster the FDA submission process for the rare autoimmune treatment. By proving that remission can be maintained without the need for additional drugs over a twelve-month period, Kyverna is attempting to establish a new benchmark for efficacy and safety in a high-risk clinical category where other developers have struggled.


Future developments will center on the formal FDA submission process for the Stiff Person Syndrome therapy. Stakeholders are watching for the completion of the BLA submission, which Kyverna aims to finalize this year. Further updates will likely focus on whether the FDA accepts the durability data as sufficient for a first-of-its-kind autoimmune CAR T approval. The industry will also monitor if the safety profile reported by Kyverna remains consistent as the patient cohort expands and more long-term data becomes available for both SPS and gMG indications.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investing.com | H.C. Wainwright reiterates Kyverna stock rating on durability data | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWTNZREw2d3lWRkF5WUJ0aDRjUHlrWEFDV0VfSTNuZXBQOWVBQld1bXFXSHlIOFo0QzN6a0NIT1VDblJ4SWlzZlVtR184bngyc1Q5cEROcEY0VjJFdzZDQ2tzeVgzU3pQcl9TTEZfUU94bEVYZ2FHOVlVTjNoWllEU095SVBpaVNmazRSdUtWWUl1UmFxSE1xbUZsWTY4VTNGSkhHby12RWZfbEdMWTlTNkNoeVNaRVcwQ3pGdDlpaTF2QQ?oc=5) |
| GenomeWeb | Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPckRlc1YwaGN0cjVRQkNoaHFUbS1RMGJBLWVwYVZzOXFEM21TQmkzM0FSX1VDSmd2N3QtV1BfUVUzYkN6TFZaRU9LRzVnLUNyaG1WczU2X00wdmIxenRwbnV5aGxwUkEtRnFiMXM2Z2k1LWJpODRtcWNxSWVjLVdmOVVzdVZISUk2c2MwbUNuR0Vubm0yVzhQajNpblFsWmln?oc=5) |
| tradingview.com | KYTX: Miv-cel delivers durable, drug-free remission and strong safety in SPS and gMG at 1 year | [Source Link](https://news.google.com/rss/articles/CBMihgJBVV95cUxQTVM4TTd0VHV1RmxmcFE0cFBlYXhnbFFRTTdrR0FJRDJJM2JMSVNzSmJRc0lyNWFxcVFJMjJyencxY1g0dnljakZQM1cxTzFRSVBic2xDMXNqcUZPeTVpNjRtWG9CZFhZWGYwbDBQajBNQm9oamxERVNnajBqWjRHMFRORGJGR2R0Q2RjVVh5bk0wUG1hWEVXYk9jOHlybEM2aVhiSEY1YldfREU3VHY1dzlSbG93clc4Vno1YWhlaWhobmtRclJuaUhCQ3NiVWxsS2RTX3JpdDhRc1Z1Z3JKemp4VTlEaWxua2xBUU15UGhtS19HNHg5RkliRnZLclg5Q3BWMTFn?oc=5) |
| BioSpace | Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxPTDczQXhTOHFKRGdYbjhnbVlaVkw4bjlyLUM5dndGSmtJaDdaSnpaMVRIeEp1NUFsUUpkOUEybldYVER2Q3VKM1JPOXVpVzdvSDAzM2Fic0EtS0RZWUJnUld6VjZ4a1dvblgwOUVnWUY4WUFtSUs0UkEtMkxFUi1HRVI3TWJnNWdxM1FhUzByODRyRGFNRVl0SUhVTXJxNThLNHdTcDVlV3dqY2tpQklGbGZUcmJBeEJuNDZmSjRUWURXOU93VElzOGF3?oc=5) |
| STAT | Kyverna’s cell therapy shows lasting autoimmune benefit | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxPU0JnYjA3ZDFmWkoyUHhUbzdFN2NNcnRBNUZaMG9pNmJDT2tqOVpkcFJZTkU3V3V5d2QxZTBVcUtwY3BOOWN5djkyT1M2QXNYN2VWZjdaNjlGcnJWajg4SkUyYlo3eGd4VDQ5YTVtaG4tUHdwWjg2aDFCcVpKYWpEWlJvOEtxalpUYlpBOGo0WGRrRXYwSld0VFlYdnJtTHhiTl94NlZB?oc=5) |
| Endpoints News | Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxON010Nm51TUtwZldONWV4RG5mV3o2ZWNKNkZjcFg0U2ZKODJkTmItdENiTWtaSGVWWDZWOEdQSmpiQW5jWmFEelpJazNHY0JabmxOX0otY0p4T1Y0OHJJN3psUzBTb2stVnppNnBEOUFkQUpKSnIyTU9MamhCRHA3djN0R0s2YmdIQUh6cTdKNjN3X2FYRlN1c3FPcEZNNEljblluQ0tOZkxVYVp3SVhUVw?oc=5) |
| Fierce Biotech | Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOMVBqX2doRTlfemVsRGYyelRJYWR3SkVxeHNPVEhWR18wOVV3MGJUZlEteTItcEx2djdTcUtHaHZtM3Z3R2VmVWtUM1BScURNRWk0VU5lLWVVQ0g5SUZ0N3VHSTlVdTBKdy1qOU1oeU1FS0FHak9WcjF0YnROLWpCY1pyeFkyeXBhUTI1bk8xdUljbS0yaWJNRXRoZldjYUt4UnRhOS1hVFBjN2V5cWs5Rw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-25/kyverna-resetting-conversation-with-1-year-miv-cel-data-as-autoimmune-car-t*